H9亚型禽流感病毒mRNA疫苗的构建与效力评价

doi:10.11843/j.issn.0366-6964.2025.04.032

Abstract

Abstract:

H9 subtype of avian influenza (AI) poses a significant threat to the poultry industry, particular the broiler industry. As current inactivated vaccine cannot effectively prevent virus infection and replication in the upper respiratory tract of chickens, it is necessary to generate an mRNA vaccine targeting the hemagglutinin (HA) gene of H9 subtype avian influenza virus (AIV). Based on the HA gene sequences available on GenBank in 2022, full-length of the HA sequences (HA) and its extracellular domain (HAe) were optimized, and cloned into the pUC57 vector to construct transcription templates in vitro. After transcription in vitro, capping, and purification, the mRNAs were encapsulated in lipid nanoparticles (LNPs) and transfected into human embryonic kidney cells (293T), baby hamster kidney cells (BHK-21), and chicken embryo fibroblast cells (DF-1). HA protein expression was confirmed via Western blot. Twenty 3-week-old SPF chickens were randomly divided into four groups (n=5). Each chicken was immunized with 0.3 mL PBS, 25 μg HA mRNA LNP, 25 μg HAe mRNA LNP and 0.3 mL H9 subtype AI inactivated vaccine, respectively. Serum samples was collected 4 weeks post-immunization to assess hemagglutination inhibition (HI) antibody titers. All animals were intranasally and ocularly challenged with 0.2 mL of H9N2 subtype AIV (containing 10^6.0EID₅₀). Oral swabs were collected 5 days post-challenge to detect virus isolation, and peripheral blood mononuclear cells (PBMCs) were collected for the measurement of expression levels of IFN-γ and IL-4, alongside observing pathological changes of tracheal tissue. Western blot analysis showed that both 2 mRNA HA proteins were successfully expressed and could be effectively translated into cells following LNP encapsulation. The mean HI antibody titers (log2) post immunization with HA mRNA LNP and HAe mRNA LNP in SPF chickens were 5.6 and 3, respectively. The H9 subtype AI inactivated vaccine induced significantly higher antibody titer (9.8), compared to both two mRNA LNP groups (P < 0.01). Virus isolation rates of the challenge control, HA mRNA LNP, HAe mRNA LNP, and H9 subtype AI inactivated vaccine groups were 5/5, 1/5, 4/5, and 2/5, respectively. The HA mRNA LNP group exhibited significantly higher IFN-γ expression levels compared to other groups (P < 0.05), while the HAe mRNA LNP group showed significantly lower IL-4 expression levels (P < 0.05). The pathological changes of tracheal tissue indicated that immunization with HA mRNA LNP and H9 subtype AI inactivated vaccine effectively mitigated damage of H9 subtype AIV to tracheal epithelial cells in SPF chickens. The constructed mRNA vaccine with HA full-length of H9N2 subtype AIV could provide an effective protection to chickens on H9 subtype AIV attack, while mRNA vaccine with HA extracellular domain could not provide an effective immune protection.

Key words: H9 subtype, avian influenza virus, mRNA vaccine, LNP, immune protection

CLC Number:

S852.659.5

HUANG Cheng, YANG Zhiyuan, LIN Jian, CHENG Huimin, WANG Mi, MAO Huilin, WANG Guoliang, LIU Guiming, ZHAO Jicheng, LIU Yuehuan. Construction and Efficacy Evaluation of mRNA Vaccines against H9 Subtype Avian Influenza Virus[J]. Acta Veterinaria et Zootechnica Sinica, 2025, 56(4): 1843-1853.

Figures/Tables 11

Fig. 1

Table 1

Table 2

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

Table 3

Fig. 8

References 29

1	GU M , XU L J , WANG X Q , et al. Current situation of H9N2 subtype avian influenza in China[J]. Vet Res, 2017, 48 (1): 49. doi: 10.1186/s13567-017-0453-2
2	ELADL A H , ARAFAT N , EL-SHAFEI R A , et al. Comparative immune response and pathogenicity of the H9N2 avian influenza virus after administration of Immulant^®, based on Echinacea and Nigella sativa, in stressed chickens[J]. Comp Immunol Microbiol Infect Dis, 2019, 65, 165- 175. doi: 10.1016/j.cimid.2019.05.017
3	WANG J L , CAO Z W , GUO X J , et al. Cytokine expression in three chicken host systems infected with H9N2 influenza viruses with different pathogenicities[J]. Avian Pathol, 2016, 45 (6): 630- 639. doi: 10.1080/03079457.2016.1193665
4	ALEXANDER D J . Newcastle disease and other avian paramyxoviruses[J]. Rev Sci Tech, 2000, 19 (2): 443- 455. doi: 10.20506/rst.19.2.1231
5	ABDEL-MONEIM A S , AFIFI M A , EL-KADY M F . Isolation and mutation trend analysis of influenza A virus subtype H9N2 in Egypt[J]. Virol J, 2012, 9, 173. doi: 10.1186/1743-422X-9-173
6	SIKHT F Z , DUCATEZ M , TOUZANI C D , et al. Avian influenza a H9N2 viruses in Morocco, 2018-2019[J]. Viruses, 2022, 14 (3): 529. doi: 10.3390/v14030529
7	SUN Y P , PU J , JIANG Z L , et al. Genotypic evolution and antigenic drift of H9N2 influenza viruses in China from 1994 to 2008[J]. Vet Microbiol, 2010, 146 (3-4): 215- 225. doi: 10.1016/j.vetmic.2010.05.010
8	LIU S , JI K , CHEN J M , et al. Panorama phylogenetic diversity and distribution of type A influenza virus[J]. PLoS One, 2009, 4 (3): e5022. doi: 10.1371/journal.pone.0005022
9	RAJÃO D S , PÉREZ D R . Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture[J]. Front Microbiol, 2018, 9, 123. doi: 10.3389/fmicb.2018.00123
10	ABDELWHAB E M , ABDEL-MONEIM A S . Epidemiology, ecology and gene pool of influenza A virus in egypt: will Egypt be the epicentre of the next influenza pandemic?[J]. Virulence, 2015, 6 (1): 6- 18. doi: 10.4161/21505594.2014.992662
11	KIM Y H , BANG Y J , PARK H J , et al. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection[J]. Vaccine, 2020, 38 (39): 6141- 6152. doi: 10.1016/j.vaccine.2020.07.022
12	ELADL A H , FARAG V M , EL-SHAFEI R A , et al. Immunological, biochemical and pathological effects of vitamin C and Arabic gum co-administration on H9N2 avian influenza virus vaccinated and challenged laying Japanese quails[J]. BMC Vet Res, 2022, 18 (1): 408. doi: 10.1186/s12917-022-03495-y
13	MEHRABADI M H F , GHALYANCHILANGEROUDI A , GHAFOURI S A , et al. Comparison of autogenous and commercial H9N2 avian influenza vaccines in a challenge with recent dominant virus[J]. Iran J Vet Res, 2020, 21 (2): 109- 114.
14	LIU M A . A comparison of plasmid DNA and mRNA as vaccine technologies[J]. Vaccines (Basel), 2019, 7 (2): 37. doi: 10.3390/vaccines7020037
15	REICHMUTH A M , OBERLI M A , JAKLENEC A , et al. mRNA vaccine delivery using lipid nanoparticles[J]. Ther Deliv, 2016, 7 (5): 319- 334. doi: 10.4155/tde-2016-0006
16	ANDERSON E J. mRNA vaccines and COVID-19-the start of a new era of vaccinology[D]. 2021.
17	SCHLAKE T , THESS A , FOTIN-MLECZEK M , et al. Developing mRNA-vaccine technologies[J]. RNA Biol, 2012, 9 (11): 1319- 1330. doi: 10.4161/rna.22269
18	PARDI N , HOGAN M J , PORTER F W , et al. mRNA vaccines—a new era in vaccinology[J]. Nat Rev Drug Discov, 2018, 17 (4): 261- 279. doi: 10.1038/nrd.2017.243
19	THESS A , GRUND S , MUI B L , et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals[J]. Mol Ther, 2015, 23 (9): 1456- 1464. doi: 10.1038/mt.2015.103
20	MAUGERI M , NAWAZ M , PAPADIMITRIOU A , et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells[J]. Nat Commun, 2019, 10 (1): 4333. doi: 10.1038/s41467-019-12275-6
21	WANG T , WEI F H , LIU J H . Emerging role of mucosal vaccine in preventing infection with avian influenza A viruses[J]. Viruses, 2020, 12 (8): 862. doi: 10.3390/v12080862
22	FAN M L , LIANG B , ZHAO Y Z , et al. Mutations of 127, 183 and 212 residues on the HA globular head affect the antigenicity, replication and pathogenicity of H9N2 avian influenza virus[J]. Transbound Emerg Dis, 2022, 69 (4): e659- e670.
23	楚电峰, 于晓璐, 孙化露, 等. mRNA技术在动物疫病疫苗中的研究进展[J]. 中国动物检疫, 2024, 41 (1): 52- 59.
	CHU D F , YU X L , SUN H L , et al. Research progress on mRNA technology in development of animal vaccines[J]. China Animal Health Inspection, 2024, 41 (1): 52- 59.
24	PETSCH B , SCHNEE M , VOGEL A B , et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection[J]. Nat Biotechnol, 2012, 30 (12): 1210- 1216. doi: 10.1038/nbt.2436
25	庄忻雨. 流感病毒mRNA疫苗的构建、制备与实验免疫研究[D]. 北京: 军事科学院, 2020.
	ZHUANG X Y. Construction, preparation and immunogenicity studies of influenza virus mRNA vaccines[D]. Beijing: Academy of Military Science, 2020.
26	XU S K , ZHANG B W , YAO J L , et al. A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection[J]. Vaccine, 2023, 41 (18): 2905- 2913. doi: 10.1016/j.vaccine.2023.03.049
27	ZHU J F , PAUL W E . Heterogeneity and plasticity of T helper cells[J]. Cell Res, 2010, 20 (1): 4- 12. doi: 10.1038/cr.2009.138
28	OKOYE I S , WILSON M S . CD4⁺ T helper 2 cells-microbial triggers, differentiation requirements and effector functions[J]. Immunology, 2011, 134 (4): 368- 377. doi: 10.1111/j.1365-2567.2011.03497.x
29	DAI M M , XU C G , CHEN W S , et al. Progress on chicken T cell immunity to viruses[J]. Cell Mol Life Sci, 2019, 76, 2779- 2788. doi: 10.1007/s00018-019-03117-1

分组group	疫苗类别 Vaccine category	免疫剂量 Immunizing dose	数量 Number
非免疫对照组	PBS	0.3 mL	5只
HA mRNA LNP组	HA mRNA LNP	25 μg	5只
HAe mRNA LNP组	HAe mRNA LNP	25 μg	5只
灭活疫苗组	H9亚型AI灭活疫苗(HP株)	0.3 mL	5只

基因gene	引物对序列(5′→3′) (F/R) sequence	序列号Accession No.
IL-4	AGCACTGCCACAAGAACCTG/TTGCCTGCTGCCGTGGGACAT	NM_001007079.2
IFN-γ	GACAAGTCAAAGCCGCACA/TCAAGTCGTTCATCGGGAGC	NM_205149.2
β-actin	CCCGTGCTGTGTTCCCATCTATCG/GGGTGCTCCTCAGGGGCTACTCTC	NM_205518.2

组别 Groups	Flu	HA+Flu	HAe+Flu	Inactivated Vac+Flu
咽喉拭子	5/5	1/5	4/5	2/5

[1]	SHI Yuting, HAN Xinyu, ZHONG Muhui, LIN Yaozhong, LIU Tengfei, LI Yan, YIN Huifang, JIA Weixin. Establishment and Validation of the Reverse Genetics System for G57 Genotype H9N2 Subgenotype Avian Influenza Virus [J]. Acta Veterinaria et Zootechnica Sinica, 2025, 56(4): 1825-1833.
[2]	GAO Zhiqiang, LAI Ping'an, SONG Yueqian, CHONG Yan, GUO Youran, BAI Zilong, GUO Huimin, WANG Lin, PU Jing, SHI Xiju, REN Tong, ZHAO Xiangpeng. Studies and Application of Multi-target Nucleic Acid Mass Spectrometry Detection Method for Avian Influenza/Newcastle Disease Virus [J]. Acta Veterinaria et Zootechnica Sinica, 2025, 56(3): 1386-1395.
[3]	LU Na, GAO Yu, ZHAO Jiawei, SU Di, CHEN Jialei, LUO Zhongli. Construction and Characterization of Transcription Vectors for Feline Infectious Peritonitis Virus mRNA Vaccines [J]. Acta Veterinaria et Zootechnica Sinica, 2025, 56(2): 803-813.
[4]	Kangning ZHAO, Zhonglong YANG, Yi CHEN, Chuncheng ZHU, Yunfei GUO, Yuncong YIN, Tao QIN, Sujuan CHEN, Daxin PENG. Genetic Variation Analysis of Sixteen Novel H3N3 Subtype Avian Influenza Viruses [J]. Acta Veterinaria et Zootechnica Sinica, 2024, 55(9): 4029-4040.
[5]	MAO Qiuyan, ZHOU Shuning, LIU Shuo, PENG Cheng, YIN Xin, ZHANG Yaxin, ZHOU Wanting, LI Jinping, HOU Guangyu, JIANG Wenming, SONG Houhui, LIU Hualei. Establishment and Application of Fluorescent Quantitative RT-PCR for Detection of H3 Subtype Avian Influenza Virus [J]. Acta Veterinaria et Zootechnica Sinica, 2024, 55(3): 1137-1146.
[6]	YANG Zhiyi, WANG Xinkai, SHI Yuting, FU Siyuan, ZHANG Yuxin, CAO Chenfu, JIA Weixin. Establishment of Nucleic Acid Detection Methods for Avian Influenza H5 Subtype Based on CRISPR-Cas13a and RT-RAA [J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(9): 3803-3811.
[7]	CHEN Xin, QIN Tong. mRNA Vaccine and Its Research Prospect in Zoonotic Diseases [J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(7): 2732-2742.
[8]	ZHOU Yong, LI Zhixin, LU Hongwei, SUN Yan, LI Tian, DU Fanshu, PU Juan. Surveillance and Outbreak Analysis of H5 and H7N9 Subtypes of Highly Pathogenic Avian Influenza in China [J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(9): 3093-3106.
[9]	CHEN Huixian, CHEN Yajie, WANG Xianmei, WANG Lifang, LIU Qun, LIU Jing. Identification of the Cross-reacting Antigen MIC17A of Toxoplasma gondii and Neospora caninum and the Study of Its Cross-immune Protective Efficacy in Mice [J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(7): 2300-2306.
[10]	CUI Mingxian, WANG Xingbo, HUANG Yanming, BIAN Xiyi, FENG Mengke, YAN Yan, DONG Weiren, ZHOU Jiyong. Genetic Characterization and Evolution of Three Strains of H3N2 Avian Influenza Viruses [J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(11): 4116-4122.
[11]	LI Tian, YANG Yang, XIE Liqing, WANG Yuanlan, LI Pan, PENG Yuanyi, LI Nengzhang. Study on the Immunoprotection of Inactivated Vaccine of Bovine Mannheimia haemolytica and Bovine Pasteurella multocida Capsular Serotype A in Mouse Model [J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(9): 2579-2588.
[12]	LIU Junwen, WU Qiongjuan, XING Gang, ZHAN Songhe, WEI Jianzhong, SUN Pei, LIU Xuelan, LI Yu. Immunogenicity Analysis and Protective Effects of CbpB Protein of Erysipelothrix rhusiopathiae in Mice [J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(6): 1689-1699.
[13]	LI Jingyun, LIAN Pengjing, BAI Yu, XI Liuqing, ZHANG Zihui, NIU Xiaofei, YANG Junqi, QIAO Jian. The Impact of H9N2 Subtype Avian Influenza Viral Infection on the Gut Flora in Mice [J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(5): 1359-1368.
[14]	LI Li, TANG Guoyi, FENG Helong, XUE Yuhan, REN Zhu, WANG Guokang, JIA Miaomiao, SHANG Yu, LUO Qingping, SHAO Huabin, WEN Guoyuan. Evaluation of Immune Efficacy of H9 Subtype Avian Influenza Virus Inactivated Vaccine Based on Mosaic HA Sequence [J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(12): 3569-3577.
[15]	XU Lei, ZHONG Jialian, YU Xunxin, LIU Yifa, HUANG Yu, LIU Xiaolong, LAI Longyong, YAN Liping, XU Xiumei, SONG Suquan, ZHANG Yuankui. Improvement of the Immune Protection Rate on Newcastle Disease Virus Attenuated Vaccine LaSota Strain by Pig Spleen Transfer Factor [J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(12): 3578-3587.

Construction and Efficacy Evaluation of mRNA Vaccines against H9 Subtype Avian Influenza Virus

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 29

Related Articles 15

Recommended Articles

Metrics

Comments